drugset / Trial / NCT00460564

Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity

NCT00460564 ↗

Phase 3 Completed 109 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS) wrist score.

Timeline

Start
2007-05
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator GSK1358820 Protein / enzyme biologic 120 iu —
Comparator GSK1358820 Protein / enzyme biologic 150 iu —
Comparator GSK1358820 Protein / enzyme biologic 200 iu —
Comparator GSK1358820 Protein / enzyme biologic 240 iu —

Indications